menu
    • menu

    Find Lifitegrast manufacturers, exporters & distributors on PharmaCompass

    Interquim Lifitegrast

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Gentec SA Lifitegrast

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    27

    API Suppliers

    API Suppliers

    12

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    4

    KDMF

    KDMF

    14

    NDC API

    NDC API

    0

    VMF

    NDC API

    23

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    10

    API

    1

    FDF

    14INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    7

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    4DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    16

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    38

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    333,902,961

    Annual Reports

    1,523

    Finished Drug Prices

    NA

    3 RELATED EXCIPIENT COMPANIES

    3EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1025967-78-5, Xiidra, Sar 1118, Sar-1118, Shp606, Shp-606
    Molecular Formula
    C29H24Cl2N2O7S
    Molecular Weight
    615.5  g/mol
    InChI Key
    JFOZKMSJYSPYLN-QHCPKHFHSA-N
    FDA UNII
    038E5L962W
    Lifitegrast
    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting.
    Lifitegrast is a Lymphocyte Function-Associated Antigen-1 Antagonist. The mechanism of action of lifitegrast is as a Lymphocyte Function-Associated Antigen-1 Antagonist.
    1 2D Structure

    Lifitegrast

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
    2.1.2 InChI
    InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
    2.1.3 InChI Key
    JFOZKMSJYSPYLN-QHCPKHFHSA-N
    2.1.4 Canonical SMILES
    CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
    2.1.5 Isomeric SMILES
    CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    038E5L962W
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (2s)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- Yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    2. L-phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-

    3. Lifitegrast Ophthalmic Solution

    4. Sar 1118

    5. Sar-1118

    6. Shp-606

    7. Shp606

    8. Xiidra

    2.3.2 Depositor-Supplied Synonyms

    1. 1025967-78-5

    2. Xiidra

    3. Sar 1118

    4. Sar-1118

    5. Shp606

    6. Shp-606

    7. (s)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    8. Chembl2048028

    9. 038e5l962w

    10. (2s)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- Yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    11. L-phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-

    12. L-phenylalanine, N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-

    13. Lifitegrast [usan:inn]

    14. Unii-038e5l962w

    15. Sar1118

    16. Xiidra (tn)

    17. Lifitegrast [mi]

    18. Lifitegrast [inn]

    19. Lifitegrast (usan/inn)

    20. Lifitegrast [usan]

    21. Lifitegrast; Sar 1118

    22. Lifitegrast [who-dd]

    23. Lifitegrast Ophthalmic Solution

    24. Gtpl7533

    25. Schembl2632068

    26. Amy4450

    27. Dtxsid60145345

    28. Lifitegrast [orange Book]

    29. Chebi:133023

    30. Ex-a2582

    31. Bdbm50386331

    32. Mfcd28502439

    33. S3714

    34. Zinc84668739

    35. Ccg-270245

    36. Cs-6264

    37. Db11611

    38. Compound 1g [pmid: 24900456]

    39. Ac-32534

    40. Ds-20052

    41. Hy-19344

    42. D10374

    43. A900838

    44. Q23044263

    45. (2s)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1h-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic Acid

    46. N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-l-phenylalanine

    47. N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-l-phenylalanine

    2.4 Create Date
    2006-12-18
    3 Chemical and Physical Properties
    Molecular Weight 615.5 g/mol
    Molecular Formula C29H24Cl2N2O7S
    XLogP34.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count7
    Exact Mass614.0681277 g/mol
    Monoisotopic Mass614.0681277 g/mol
    Topological Polar Surface Area142 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity1100
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome).

    FDA Label

    Treatment of dry eye disease

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Lifitegrast addresses both the symptoms and the resulting ocular surface damage by interfering with ocular inflammatory cycle. Lifitegrast is a lymphocyte functionassociated antigen-1 antagonist through direct competitive antagonism and sequentially inhibits the T-cell recruitment, activation, and proinflammatory cytokine release associated with dry eye syndrome.

    5.2 MeSH Pharmacological Classification

    Ophthalmic Solutions

    Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (See all compounds classified as Ophthalmic Solutions.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    LIFITEGRAST
    5.3.2 FDA UNII
    038E5L962W
    5.3.3 Pharmacological Classes
    Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]; Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]
    5.4 ATC Code

    S - Sensory organs

    S01 - Ophthalmologicals

    S01X - Other ophthalmologicals

    S01XA - Other ophthalmologicals

    S01XA25 - Lifitegrast

    5.5 Absorption, Distribution and Excretion

    Absorption

    The mean peak plasma concentration (Cmax) of 1.70ng/mL was reached within 15 minutes of application. Quantifiable trough plasma concentrations ranged from 0.55 ng/mL to 3.74 ng/mL. Observations show limited systemic exposure that produces significant clinical outcomes.

    Route of Elimination

    Not possible to perform mass balance study to determine the main route of elimination.

    Clearance

    Not possible to calculate clearance rate based on plasma concentrations of lifitegrast, but reported to be relatively fast in rat I.V. pharmacokinetics study. It is predicted that lifitegrast is cleared via nasal and subsequently gastrointestinal tract.

    5.6 Metabolism/Metabolites

    Based on the findings of an in vitro metabolism study using fresh human hepatocytes, lifitegrast does not appear to undergo significant metabolism.

    5.7 Biological Half-Life

    Not possible to calculate plasma elimination half-life based on plasma concentrations of lifitegrast, but reported to be relatively short in rat I.V. pharmacokinetics study.

    5.8 Mechanism of Action

    Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell proliferation/activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines, inflammatory mediators, chemokines, TNF-, and IL-1 in human peripheral blood mononuclear cells.

    USDMF

    read-more
    read-more

    01

    Interquim Sa

    Spain
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35652

    Submission : 2022-07-18

    Status : Active

    Type : II

    Interquim

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr Reddys Laboratories Ltd

    India
    arrow
    CPhI India 2024
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2019-10-29

    Pay. Date : 2019-09-27

    DMF Number : 33681

    Submission : 2019-03-29

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    SupplySide West 2024
    Not Confirmed

    03

    Apitoria Pharma Private Ltd

    India
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-03-09

    Pay. Date : 2020-02-13

    DMF Number : 34576

    Submission : 2020-02-15

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    SupplySide West 2024
    Not Confirmed

    04

    Guang'an Kingday Pharma And Chem Co ...

    China
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38179

    Submission : 2023-04-20

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    SupplySide West 2024
    Not Confirmed

    05

    Glenmark Life Sciences Ltd

    India
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2019-04-23

    Pay. Date : 2019-03-28

    DMF Number : 33711

    Submission : 2019-03-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Micro Labs Ltd

    India

    USDMF

    arrow
    SupplySide West 2024
    Not Confirmed

    06

    Micro Labs Ltd

    India
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-06-02

    Pay. Date : 2020-05-08

    DMF Number : 34735

    Submission : 2020-04-29

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    SupplySide West 2024
    Not Confirmed

    07

    Msn Life Sciences Private Ltd

    India
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34280

    Submission : 2019-11-02

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Olon Spa

    Italy

    USDMF

    arrow
    SupplySide West 2024
    Not Confirmed

    08

    Olon Spa

    Italy
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-04-14

    Pay. Date : 2020-01-27

    DMF Number : 34551

    Submission : 2020-02-04

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Olon Spa

    Italy

    USDMF

    arrow
    SupplySide West 2024
    Not Confirmed

    09

    Olon Spa

    Italy
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37215

    Submission : 2022-09-26

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Scinopharm Taiwan Ltd

    Taiwan

    USDMF

    arrow
    SupplySide West 2024
    Not Confirmed

    10

    Scinopharm Taiwan Ltd

    Taiwan
    arrow
    SupplySide West 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2024-07-01

    Pay. Date : 2024-06-06

    DMF Number : 35421

    Submission : 2020-12-28

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search